comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-28 09:24:15 - browse：265

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Travel bans should be based on evidence, not politics or fear

hotspot

focus

WSS

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Humana CEO Bruce Broussard to step down in 2024

A fraught question for the kids of Alzheimer’s: Is it coming for us?

‘The Bear’ and hospitality in hospitals

CDC launches VaccineFinder tool to locate Covid

Ohioans vote in high

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Ohioans vote in high

Medical records are filled with copy

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Alkermes shareholders re

European regulators recommend Amylyx's ALS drug be rejected

How one medical school became remarkably diverse

Female surgeons have lower rates of long

In age of alternative facts, a scholarly course on calling out crap

Wellcome Trust names Røttingen as its new CEO

focus

Astronauts get first look at the spacecraft that will fly them around the moon

Wegovy cuts risk of cardiovascular events by 20%, study finds

Wegovy cuts risk of cardiovascular events by 20%, study finds

How clinical AI models' predictive power can degrade over time

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Researchers CRISPR chickens in bid to protect them from bird flu

focus

Wikipedia

focus

entertainment